Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain
Novo Nordisk’s $1 billion bet last year on a small Canadian biotech could expand the Danish drug giant’s arsenal of obesity medicines …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
